Menu Search
Equities

Glaukos Corp

GKOS:NYQ

Glaukos Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)142.94
  • Today's Change-1.06 / -0.74%
  • Shares traded661.95k
  • 1 Year change+126.46%
  • Beta1.0401
Data delayed at least 15 minutes, as of Nov 26 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform5
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for Glaukos Corp have a median target of 145.00, with a high estimate of 155.00 and a low estimate of 115.00. The median estimate represents a 0.69% increase from the last price of 144.00.
High7.6%155.00
Med0.7%145.00
Low-20.1%115.00

Earnings history & estimates in USD

On Nov 04, 2024, Glaukos Corp reported 3rd quarter 2024 losses of -0.28 per share. This result exceeded the -0.48 consensus loss of the 12 analysts covering the company and exceeded last year's 3rd quarter results by 44.00%.
The next earnings announcement is expected on Feb 19, 2025.
Average growth rate+8.69%
Glaukos Corp reported annual 2023 losses of -2.27 per share on Feb 21, 2024.
Average growth rate-46.32%
More ▼

Revenue history & estimates in USD

Glaukos Corporation had 3rd quarter 2024 revenues of 96.67m. This bettered the 91.49m consensus of the 11 analysts covering the company. This was 30.81% above the prior year's 3rd quarter results.
Average growth rate+5.57%
Glaukos Corporation had revenues for the full year 2023 of 314.71m. This was 11.26% above the prior year's results.
Average growth rate+8.27%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.